<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor XIII, concentrate from human plasma: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor XIII, concentrate from human plasma: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor XIII, concentrate from human plasma: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16473" href="/d/html/16473.html" rel="external">see "Factor XIII, concentrate from human plasma: Drug information"</a> and <a class="drug drug_patient" data-topicid="16474" href="/d/html/16474.html" rel="external">see "Factor XIII, concentrate from human plasma: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12871939"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Corifact</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871254"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Corifact 1250;</li>
<li>Corifact 250</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F14856201"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block don drugH1Div" id="F54297091"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="793db234-183b-42f6-bcdc-fc7cabc2e53d">Congenital factor XIII deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital factor XIII deficiency:</b> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 40 units/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Adjust dose in 5 units/kg increments based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom activity assay) and clinical response; repeat every 28 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Factor XIII Activity Trough Level (%):</p>
<p style="text-indent:-2em;margin-left:10em;">One trough level &lt;5%: Increase dosage by 5 units/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Trough level 5% to 20%: No dosage change.</p>
<p style="text-indent:-2em;margin-left:10em;">Two trough levels &gt;20%: Decrease dosage by 5 units/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">One trough level &gt;25%: Decrease dosage by 5 units/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, perioperative management of surgical bleeding:</i> Individualize dosing based on factor XIII activity level, type of surgery, and clinical response; monitor factor XIII activity levels during and after surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">If time since last prophylactic dose ≤7 days: Additional dose may not be needed.</p>
<p style="text-indent:-2em;margin-left:6em;">If time since last prophylactic dose 8 to 21 days: Additional partial or full dose may be necessary based on factor XIII activity level.</p>
<p style="text-indent:-2em;margin-left:6em;">If time since last prophylactic dose 21 to 28 days: Administer full prophylactic dose.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F11595766"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="793db234-183b-42f6-bcdc-fc7cabc2e53d">Congenital factor XIII deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital factor XIII deficiency:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 40 units/kg</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Adjust dose in 5 units/kg increments based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom activity assay) and clinical response; repeat every 28 days</p>
<p style="text-indent:-2em;margin-left:8em;">Factor XIII Activity Trough Level (%):</p>
<p style="text-indent:-2em;margin-left:10em;">One trough level &lt;5%: Increase dosage by 5 units/kg</p>
<p style="text-indent:-2em;margin-left:10em;">Trough level 5% to 20%: No dosage change</p>
<p style="text-indent:-2em;margin-left:10em;">Two trough levels &gt;20%: Decrease dosage by 5 units/kg</p>
<p style="text-indent:-2em;margin-left:10em;">One trough level &gt;25%: Decrease dosage by 5 units/kg</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, perioperative management of surgical bleeding:</i> Individualize dosing based on factor XIII activity level, type of surgery, and clinical response; monitor factor XIII activity levels during and after surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">If time since last prophylactic dose ≤7 days: Additional dose may not be needed.</p>
<p style="text-indent:-2em;margin-left:6em;">If time since last prophylactic dose 8 to 21 days: Additional partial or full dose may be necessary based on factor XIII activity level.</p>
<p style="text-indent:-2em;margin-left:6em;">If time since last prophylactic dose 21 to 28 days: Administer full prophylactic dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109811"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51109812"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F11595767"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16473" href="/d/html/16473.html" rel="external">see "Factor XIII, concentrate from human plasma: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="793db234-183b-42f6-bcdc-fc7cabc2e53d">Congenital factor XIII deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Congenital factor XIII deficiency:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 40 units/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Maintenance: Dose adjustment should be based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom activity assay) and clinical response; repeat every 28 days.</p>
<p style="text-indent:-2em;margin-left:6em;">One trough level of &lt;5%: Increase dosage by 5 units/kg</p>
<p style="text-indent:-2em;margin-left:6em;">Trough level of 5% to 20%: No dosage change</p>
<p style="text-indent:-2em;margin-left:6em;">Two trough levels of &gt;20%: Decrease dosage by 5 units/kg</p>
<p style="text-indent:-2em;margin-left:6em;">One trough level of &gt;25%: Decrease dosage by 5 units/kg</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Perioperative management of surgical bleeding:</i>
<b>IV</b>: 10 to 50 units/kg has been reported in clinical practice but because congenital factor XIII deficiency is a rare disorder, data are limited (Janbain 2015; Naderi 2017). Individualize dosing based on factor XIII activity level, type of surgery, and clinical response; monitor factor XIII activity levels during and after surgery:</p>
<p style="text-indent:-2em;margin-left:4em;">If time since last prophylactic dose ≤7 days: Additional dose may not be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">If time since last prophylactic dose 8 to 21 days: Additional partial or full dose may be necessary based on factor XIII activity level.</p>
<p style="text-indent:-2em;margin-left:4em;">If time since last prophylactic dose 21 to 28 days: Administer full prophylactic dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990487"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987772"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F11595725"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (1% to 2%), pruritus (1% to 2%), skin rash (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood (elevated thrombin-antithrombin levels: 1% to 2%), hematoma (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 2%; can be severe hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 2%), arthritis (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ischemia (acute)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (neutralizing)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Cardiovascular: Thromboembolic complications</p></div>
<div class="block coi drugH1Div" id="F11595712"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of anaphylaxis or severe systemic reactions to human plasma-derived products or hypersensitivity to any component of the formulation</p></div>
<div class="block war drugH1Div" id="F11595713"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of factor XIII inhibitory antibodies has been reported. Factor XIII inhibitory antibodies should be measured when clinical response (breakthrough bleeding) and/or factor XIII trough levels are suboptimal after apparent adequate dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use; discontinue immediately if develops and initiate appropriate management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thromboembolic events have been reported. Use with caution in patients with known risk factors for thrombosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Vaccination with hepatitis A and hepatitis B vaccines is recommended.</p></div>
<div class="block dosfc drugH1Div" id="F51237131"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Potency is shown as a range for each vial (1,000 to 1,600 units/vial). The actual units of potency of FXIII are stated on each vial label and carton.</p></div>
<div class="block foc drugH1Div" id="F12871940"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Corifact: 1000 - 1600 units [contains albumin human]</p></div>
<div class="block geq drugH1Div" id="F11595705"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F21121601"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Corifact Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000-1600 unit (Price provided is per AHF Unit): $14.45</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871255"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Corifact 250: 250 units (1 ea) [contains albumin human]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Corifact 1250: 1250 units (1 ea) [contains albumin human]</p></div>
<div class="block admp drugH1Div" id="F52614477"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer by IV infusion at a rate not to exceed 4 mL/minute. Administer through a separate infusion line.</p></div>
<div class="block adm drugH1Div" id="F11595769"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by IV infusion at a rate not to exceed 4 mL/minute. Product should be brought to room temperature prior to infusing. Administer through a separate infusion line.</p></div>
<div class="block sts drugH1Div" id="F11595754"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. May be stored at room temperature (≤25°C [≤77°F]) for up to 6 months; do not return to refrigerator if stored at room temperature.</p></div>
<div class="block usep drugH1Div" id="F53570918"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis against bleeding episodes and management of perioperative surgical bleeding in patients with congenital factor XIII deficiency (FDA approved in all ages).</p></div>
<div class="block mst drugH1Div" id="F11595805"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor XIII may be confused with Factor VIII</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299310"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F12608729"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F11595710"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant patients with factor XIII deficiency may have an increased risk of bleeding following abortion, antenatal procedures, and delivery. There is also a high rate of pregnancy loss without treatment; close surveillance is recommended. Maternal factor XIII concentrations decrease during pregnancy and dosing frequency should be increased. Additional treatment may be needed prior to delivery or procedures. Factor XIII concentrate (human) may be used in patients with a factor XIII deficiency (RCOG [Pavord 2017]).</p></div>
<div class="block mopp drugH1Div" id="F53570919"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Factor XIII trough levels in conjunction with clinical response to assess efficacy (ie, approximately every 28 days for prophylaxis, during and after surgery for perioperative management of surgical bleeding). Factor XIII inhibitory antibodies if inadequate clinical response and/or factor XIII trough levels are suboptimal. Signs/symptoms of hypersensitivity reactions, thrombotic events, and infection.</p></div>
<div class="block pha drugH1Div" id="F11595756"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Factor XIII (FXIII) is an endogenous plasma glycoprotein found in platelets, monocytes and macrophages that is converted to activated factor XIII (FXIIIa) in the presence of calcium ions.  Once activated, FXIIIa cross-links fibrin and cross-links plasmin inhibitor to protect and strengthen the hemostatic platelet plug.</p></div>
<div class="block phk drugH1Div" id="F11595758"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration of effect: Plasma levels of FXIII: ~28 days; FXIII activity maintained at ≥5% in ≥97% of patients and ≥10% in ≥85% of patients</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 51.1 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Factor XIII, a proenzyme, is converted to activated factor XIII</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children (&lt;16 years): 5.7 ± 1 days; Adults: 7.1 ± 2.7 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1.7 hours postinfusion</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: </p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients &lt;16 years: 0.29 ± 0.12 mL/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.22 ± 0.07 mL/hour/kg</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12992821"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cluvot | Fibrogammin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin hs</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cluvot</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cluvot</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin | Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cluviat</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cluvot</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cluvot | Factor xiii | Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cluvot | Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cluvot | Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Corifact</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cluvot | Fibrogammin p</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fibrogammin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cluvot</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cluvot | Fibrogammin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Corifact (factor XIII concentrate, human) [prescribing information]. Kankakee, IL: CSL Behring LLC; December 2019.</div>
</li>
<li>
<div class="reference">
                  Corifact (Factor XIII concentrate, Human) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; January 2018.</div>
</li>
<li>
<div class="reference">
                  Hsieh L and Nugent D, “Factor XIII Deficiency,” <i>Haemophilia</i>, 2008, 14(6):1190-200.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070582">
<a name="25070582"></a>Janbain M, Nugent DJ, Powell JS, St-Louis J, Frame VB, Leissinger CA. Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. <i>Transfusion</i>. 2015;55(1):45-50. doi:10.1111/trf.12784<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-xiii-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/25070582/pubmed" id="25070582" target="_blank">25070582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19598071">
<a name="19598071"></a>Karimi M, Bereczky Z, Cohan N, et al, “Factor XIII Deficiency,” <i>Semin Thromb Hemost</i>, 2009, 35(4):426-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-xiii-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/19598071/pubmed" id="19598071" target="_blank">19598071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29028293">
<a name="29028293"></a>Naderi M, Haghpanah S, Miri-Aliabad G, Tavosi H, Karimi M. A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran. <i>J Thromb Haemost.</i> 2017;15(12):2300-2305. doi:10.1111/jth.13872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-xiii-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/29028293/pubmed" id="29028293" target="_blank">29028293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-xiii-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 105600 Version 64.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
